

RECEIVED

OCT 29 2001 # 5

117
TECH CENTER 1600/2900

PATENT
Customer Number: 22,852

Attorney Docket No. 4853.0068-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Katsuhiko MIKOSHIBA et al.

)
)
) Group Art Unit: 1646

Application No.: 09/832,189

)
) Examiner: To be assigned

Filed: April 11, 2001

For: TRUNCATED REELIN
PROTEIN AND DNA
ENCODING THE SAME

)
)
)
)
)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO 1449. This Information Disclosure Statement is being filed, to the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application.

Each document listed on the attached Form PTO 1449 was cited in a communication in a counterpart European Patent Application and this Information Disclosure Statement is being filed within three months of the mailing date printed on that communication. Applicants submit a copy of this communication and the listed documents. Applicants respectfully request that the Examiner consider the documents and indicate that they were considered by making appropriate notations on the attached form.

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

RECEIVED
TECH CENTER 1600/2900
OCT 25 PM 3:20

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 25, 2001

By: *Robert V. Mann* ^{Reg. No. 44,555} *for Jean Fordis*
Jean B. Fordis
Reg. No. 32,984

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	4853.0068-00	Serial No.	09/832,189
Applicant	Katusuhiko MIKOSHIBA et al.		
Filing Date	April 11, 2001	Group:	1646

RECEIVED
TECH CENTER 1000/2000
01 OCT 25 PM 3

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	D'Arcangelo, G., et al., "Reelin Is a Secreted Glycoprotein Recognized by the CR-50 Monoclonal Antibody," <i>The Journal of Neuroscience</i> , Vol. 17, pp. 23-31, (1997).
	D'Arcangelo, G., et al., "A Protein Related to Extracellular Matrix Proteins Deleted in the Mouse Mutant <i>Reeler</i> ," <i>Nature</i> , Vol. 374, pp. 719-723, (1995).
	Hiesberger, T., et al., "Direct Binding of Reelin to VLDL Receptor and ApoE Receptor 2 Induces Tyrosine Phosphorylation of Disabled-1 and Modulates Tau Phosphorylation," <i>Neuron</i> , Vol. 24 pp. 481-489 (1999).
	Hoshino, J., et al., "Identification of MR-1, Novel Alternative Splicing Isoforms of Reelin, in the Developing Mouse Brain." <i>Society for Neuroscience Abstracts</i> , Vol. 26, No. 1-2, Abstract no. -25.12 (2000).
	Tabata, H., et al., "Identification of a <i>Xenopus Reelin</i> Fragment, which has a Sequence Highly Homologous to the Mouse/Human <i>Reelin</i> ." <i>Society for Neuroscience Abstracts</i> , Vol. 24, No. 1-2, p. 1772, (1998).
	Tabata, H., et al., "Identification of a Novel Isoform of <i>Reelin</i> in <i>Xenopus</i> , Which Contains the F-Spondin Domain and the CR-50 Epitope Region but Lacks the Reelin Repeats." <i>Society for Neuroscience Abstracts</i> , Vol. 25, No. 1-2, p. 245, (1999).
	European Search Report, for European Patent Application No. EP 01 30 3411, dated September 20, 2001.

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce